START WITH YOUR QUESTION
Explore the evidence by outcome
Find what has been assessed, who or what was studied, and the limits of the finding.
This finder uses the same selected-source assessments as the peptide and stack guides. Evidence types describe the underlying source research, which may be indirect for the requested outcome. Filters select existing assessments; they do not recalculate grades or establish treatment recommendations. Topics without an outcome assessment remain in the peptide directory.
32 assessments match these filters. Showing 12 on page 2 of 2.
BPC-157 · Peptide assessment
Reported symptom changes
Human research
- Population / model
- 1,039 documented users;354 with response direction
- Formulation / route
- Study-specific; no cross-route equivalence assumed
- Study design
- Retrospective clinical-note study; preprint not peer reviewed
A September 2026 preprint identified 1,039 documented users; 279 of the 354 with a recorded response direction had reported improvement, while 685 lacked a recorded response direction.[1] It was not peer reviewed at this check, and missing outcomes, co-treatments and no control group prevent interpreting these counts as an effectiveness rate.[1] The much larger number of documented users improves the description of real-world use, but it does not resolve the missing outcomes or introduce the comparison group needed to estimate a treatment effect.[1]
Main limitation: Selection, missingness and confounding.[1]
KLOW stack · Stack assessment
Safety of KPV-containing combinations
Context sources
- Population / model
- Human safety information is insufficient
- Formulation / route
- KPV-containing drug products
- Study design
- Regulatory safety assessment
FDA identifies a major human safety-information gap for KPV.[2]
Main limitation: A safety-information gap cannot establish that a combination is safe or quantify its risk.[2]
Collagen peptides · Peptide assessment
Short-term skin elasticity
Human research
- Population / model
- 69 women aged 35–55, eight weeks
- Formulation / route
- Oral collagen hydrolysate
- Study design
- Small randomized double-blind placebo-controlled trial
A randomized trial reported improved skin elasticity with a specific oral collagen preparation.[3] In one double-blind trial, 69 women aged 35–55 were assigned collagen hydrolysate or placebo for eight weeks; elasticity improved relative to placebo, while moisture-related findings were not statistically significant.[3] This is a short-term signal in a narrow population rather than proof of broad skin rejuvenation.[3]
Main limitation: Short duration, narrow population, and product-specific findings.[3]
GLOW stack · Stack assessment
Skin improvement from the GLOW blend
Human research
- Population / model
- 13 completers after CO2 laser resurfacing
- Formulation / route
- Topical GHK-Cu, not the injected three-peptide blend
- Study design
- Indirect topical human trial
This study tests a skin regimen rather than GLOW.[4]
Main limitation: Route and intervention differ from the stack.[4]
Ipamorelin · Peptide assessment
Sleep quality or training recovery
Human research
- Population / model
- Healthy volunteers and postoperative bowel-resection patients
- Formulation / route
- Intravenous studies; subcutaneous combination claims not established
- Study design
- Human pharmacology and unrelated clinical-indication studies
The human studies reviewed here do not establish that ipamorelin improves sleep quality or training recovery, either alone or combined with CJC-1295.[5][6] Early human work examined its pharmacokinetics and growth-hormone response, while a later randomized trial studied intravenous ipamorelin after bowel surgery.[5][6] Neither setting directly tests the sleep or recovery claims made for subcutaneous combinations.[5][6]
Main limitation: No matched clinical-outcome trial identified for these claims.[5][6]
CJC-1295 + ipamorelin · Stack assessment
Sleep, muscle, or recovery benefit from the pair
Human research
- Population / model
- Healthy adult volunteers
- Formulation / route
- Long-acting CJC-1295 or intravenous ipamorelin, studied separately
- Study design
- Indirect single-agent human studies
Separate hormone-response studies cannot establish the combination’s clinical benefit.[5][7]
Main limitation: The intervention and endpoints differ from the stack claims.[5][7]
BPC-157 · Peptide assessment
Structural tendon or ligament healing
Human and preclinical research
- Population / model
- Knee-pain patients and surgically injured rats
- Formulation / route
- Study-specific; no cross-route equivalence assumed
- Study design
- Human case series indirect for structural repair; exploratory rat repair experiment
The knee-pain case series measured subjective symptoms, without objective confirmation of tendon or ligament repair.[8] In a 2026 rat Achilles-repair experiment, BPC-157 alone did not significantly improve maximum load to failure versus control.[9] That experiment used four tendons per group for each endpoint, so its nonsignificant result does not establish that no effect exists.[9]
Main limitation: Symptoms and preclinical endpoints do not establish human structural repair.[8][9]
GHK-Cu · Peptide assessment
Topical skin-quality improvement
Human research
- Population / model
- 13 completers after CO2 laser resurfacing
- Formulation / route
- Topical copper-tripeptide skin-care regimen
- Study design
- Small randomized post-procedure trial
The selected topical trial provides limited, procedure-specific evidence for GHK-Cu.[4] In a randomized study after carbon dioxide laser resurfacing, 13 patients completed follow-up.[4] Participants using the copper-peptide regimen reported greater improvement in overall skin quality, but objective assessments found no significant between-group improvement in wrinkles, overall skin quality, or resolution of redness.[4]
Main limitation: Small sample, mixed endpoints, procedure-specific context.[4]
Tirzepatide · Peptide assessment
Weight maintenance after continuation versus withdrawal
Human research
- Population / model
- 670 participants randomized after 36 weeks of treatment
- Formulation / route
- Continuation or withdrawal of subcutaneous tirzepatide
- Study design
- Randomized withdrawal trial after open-label lead-in
Many participants regained weight after tirzepatide withdrawal in SURMOUNT-4.[10] After a 36-week initial treatment period, 670 participants were randomized either to continue tirzepatide or switch to placebo.[10] During the next 52 weeks, the placebo group gained an average 14.0% relative to its weight at randomization, while those continuing tirzepatide lost a further 5.5%.[10]
Main limitation: Enriched for participants able to reach randomization.[10]
Semaglutide · Peptide assessment
Weight reduction over 68 weeks
Human research
- Population / model
- 1,961 adults with overweight or obesity without diabetes
- Formulation / route
- Studied subcutaneous pharmaceutical formulation
- Study design
- Large double-blind randomized placebo-controlled trial
In STEP 1, 1,961 adults with overweight or obesity without diabetes were randomized to subcutaneous semaglutide or placebo, both alongside lifestyle intervention.[11] At 68 weeks, average weight change was −14.9% with semaglutide and −2.4% with placebo.[11] This provides strong evidence of average weight reduction in the studied population, but it is not a forecast for an individual or evidence for an unverified research-use product.[11]
Main limitation: Average trial response does not predict an individual's result.[11]
Tirzepatide · Peptide assessment
Weight reduction over 72 weeks
Human research
- Population / model
- 2,539 adults with overweight or obesity without diabetes
- Formulation / route
- Studied subcutaneous pharmaceutical formulation
- Study design
- Large double-blind randomized placebo-controlled trial
SURMOUNT-1 randomized 2,539 adults with obesity, or overweight with a weight-related complication, without diabetes.[12] Across the three studied tirzepatide groups, average weight reduction at 72 weeks ranged from 15.0% to 20.9%, compared with 3.1% with placebo.[12] The size and randomized design support a strong conclusion about average weight reduction under the trial conditions.[12]
Main limitation: Effects depend on the studied population and treatment conditions.[12]
Semaglutide · Peptide assessment
Weight regain after withdrawal
Human research
- Population / model
- 327 participants in the STEP 1 extension
- Formulation / route
- Withdrawal after studied subcutaneous semaglutide
- Study design
- Observational extension of a randomized trial
Weight regain was substantial after treatment ended in the STEP 1 extension.[13] In the extension group, participants previously assigned semaglutide regained an average 11.6 percentage points of body weight during the following year, approximately two-thirds of their earlier loss, leaving an average net reduction of 5.6% from the original baseline.[13] This was follow-up of a subset of the original trial, and structured lifestyle intervention also stopped, so it cannot isolate every contributor to regain.[13]
Main limitation: Selected follow-up subset; drug and lifestyle intervention both stopped.[13]
How certainty is assessed · Study reviews and review coverage